Investigational drug · Phase 2
WAL0921
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "WAL0921"
First trial start
2024
Jul 2, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "WAL0921", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diabetic Nephropathies
- Primary Focal Segmental Glomerulosclerosis
- Minimal Change Disease
- Primary Immunoglobulin A Nephropathy
- Primary Membranous Nephropathy
Approved drugs for the same conditions: IgA nephropathy · Cardiovascular and metabolic · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "WAL0921" as an intervention, largest first.
Walden BiosciencesIndustry
NCT06466135 · 96 participants (planned) · Start Jul 2, 2024 · Primary completion Mar 2027
Drug: WAL0921; Placebo · For: Diabetic Nephropathies; Primary Focal Segmental Glomerulosclerosis; Minimal Change Disease and 2 more
Sites: Los Angeles, California; Denver, Colorado; Tamarac, Florida · 50 sites in all
Walden BiosciencesIndustry
NCT05891366 · 40 participants · Start May 31, 2023 · Primary completion Jan 9, 2024
Drug: WAL0921; Placebo · For: Healthy
Sites: Austin, Texas
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Diabetic Nephropathies
- CU01-1001Phase 21 trial
Curacle Co., Ltd. · Diabetic Nephropathies
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.